Dr. Sylvain Bourgoin receives a research grant for his project entitled: Role of phosphatidylserine-specific phospholipase A1 (PLA1A) in the pathogenesis of rheumatic diseases.
Project summary :
Understanding inflammatory arthritis on the path to tailored treatment
While treatments have advanced for inflammatory arthritis, not all people respond the same way, and available therapies can have significant side effects. Understanding more about these diseases may shed light on new approaches to treatment and how to tailor them to different disease subsets. Researchers identified a protein marker found at high levels in the blood and synovial (joint) fluid of some with different forms of inflammatory arthritis. Dr. Sylvain Bourgoin will now determine how this protein marker contributes to these diseases and other co-existing health issues by studying the marker in blood from people with early arthritis or lupus and following them over two years, and by studying the role of this protein in lab mouse models. These insights could eventually guide the development of new treatments for the subset of people with inflammatory arthritis and high levels of this marker.
For more information, please visit Arthritis Society Canada’s website.